GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (BSP:B1GN34) » Definitions » Shiller PE Ratio

BeiGene (BSP:B1GN34) Shiller PE Ratio : (As of Jun. 10, 2024)


View and export this data going back to 2020. Start your Free Trial

What is BeiGene Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BeiGene Shiller PE Ratio Historical Data

The historical data trend for BeiGene's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Shiller PE Ratio Chart

BeiGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BeiGene Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BeiGene's Shiller PE Ratio

For the Biotechnology subindustry, BeiGene's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeiGene's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeiGene's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BeiGene's Shiller PE Ratio falls into.



BeiGene Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

BeiGene's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, BeiGene's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.946/131.7762*131.7762
=-0.946

Current CPI (Mar. 2024) = 131.7762.

BeiGene Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.000 100.560 0.000
201409 -0.033 100.428 -0.043
201412 -0.014 99.070 -0.019
201503 -0.046 99.621 -0.061
201506 -0.025 100.684 -0.033
201509 -0.078 100.392 -0.102
201512 -0.258 99.792 -0.341
201603 -0.259 100.470 -0.340
201606 -0.205 101.688 -0.266
201609 -0.260 101.861 -0.336
201612 -0.244 101.863 -0.316
201703 -0.313 102.862 -0.401
201706 -0.395 103.349 -0.504
201709 0.626 104.136 0.792
201712 -0.553 104.011 -0.701
201803 -0.525 105.290 -0.657
201806 -0.830 106.317 -1.029
201809 -0.781 106.507 -0.966
201812 -1.359 105.998 -1.690
201903 -0.845 107.251 -1.038
201906 -0.424 108.070 -0.517
201909 -1.607 108.329 -1.955
201912 -2.011 108.420 -2.444
202003 -1.768 108.902 -2.139
202006 -1.712 108.767 -2.074
202009 -1.998 109.815 -2.398
202012 -2.058 109.897 -2.468
202103 0.282 111.754 0.333
202106 -2.023 114.631 -2.326
202109 -1.918 115.734 -2.184
202112 -2.658 117.630 -2.978
202203 -1.642 121.301 -1.784
202206 -2.120 125.017 -2.235
202209 -2.150 125.227 -2.262
202212 -1.731 125.222 -1.822
202303 -1.354 127.348 -1.401
202306 -1.359 128.729 -1.391
202309 0.741 129.860 0.752
202312 -1.323 129.419 -1.347
202403 -0.946 131.776 -0.946

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BeiGene  (BSP:B1GN34) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


BeiGene Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of BeiGene's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene (BSP:B1GN34) Business Description

Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (BSP:B1GN34) Headlines

No Headlines